

**New York State Medicaid
NYRx Preferred Drug Program - 2025 Therapeutic Class Reviews
Preferred Drug Program Legislation**

The New York State Medicaid Drug Utilization Review (DUR) Board intends to review the following therapeutic classes in 2025 as they pertain to the NYRx Preferred Drug Program (PDP). For the therapeutic classes listed below, new relevant clinical and/or financial information is known to exist.

Therapeutic Category	Therapeutic Class	Previous Review Date
Anti-Infectives	Anti-Virals - Oral	6/15/2012
Cardiovascular	Beta Blockers	6/27/2013
Central Nervous System	Antimigraine Agents - Other	9/21/2023
	Antipsychotics - Second Generation	9/21/2023
	Sedative Hypnotics / Sleep Agents	4/22/2015
Endocrine and Metabolic Agents	Glucagon Agents	5/18/2023
	Insulin - Rapid Acting	9/17/2015
Hematological Agents	Colony Stimulating Factors	5/13/2021
	Hemophilia Agents - Other	Initial Review
	Platelet Inhibitors	4/27/2017
Immunologic Agents	Immunomodulators - Systemic	5/16/2024
Ophthalmics	Prostaglandin Agonists - Ophthalmic	9/20/2018
Renal and Genitourinary	Alpha Reductase Inhibitors for BPH	6/27/2013
	Urinary Tract Antispasmodics	5/18/2023
Respiratory	COPD Agents	5/18/2023

Please refer to [NYRx Preferred Drug List \(PDL\)](#) for the list of drugs in the therapeutic class.

As of April 2025, no relevant new clinical and/or financial information is known to exist for the remaining PDP therapeutic classes, since previously reviewed, and the DOH proposes no changes to the NYRx PDL. If interested parties have new relevant clinical information, it can be submitted to dur@health.ny.gov as it becomes available. When submitting new relevant clinical information, please reference the DUR Board and PDP therapeutic Class. DOH will consider new relevant clinical information submitted when developing future DUR Board meeting agendas.

In determining and submitting new clinical information, the previous review dates for all therapeutic classes are available on prior meeting agendas which may be viewed at the [DUR Program](#) webpage. New clinical information may include a new drug or drug product information, new indications, new safety information or new published clinical trials. Comparative evidence is preferred, or placebo controlled when no head-to-head trials are available. Information in abstract form alone, posters, or unpublished data are poor quality evidence for the purpose of review and submission is discouraged.

DUR Board meeting agendas are posted to the [DUR Program](#) webpage thirty (30) days prior to the meeting date. Please monitor the [DUR Program](#) webpage for DUR Board meeting schedules and agendas.